i-Pharm GxP’s Post

Scaling CAR-T Manufacturing 🚀 Exciting news from Kite Pharma, a Gilead Sciences subsidiary, is on the brink of enhancing CAR-T cell therapy production. They've teamed up with Cellares to explore the potential of the innovative Cell Shuttle platform🤝 This collaboration marks another strategic move by Kite, following their recent partnership with Cytiva. The aim is to ultimately revolutionize how we manufacture life-saving therapies. In a world where efficiency is key, imagine 90% less labor, less space, and a 50% reduction in batch cost. Chris McDonald of Kite, highlighted the importance of evolving manufacturing for better delivery to patients and physicians👩⚕️ Cellares' Cell Shuttle could be a game-changer, boasting a truck-sized automated unit promising to streamline the entire manufacturing process. This might just translate into easier access to therapies for a multitude of diseases - Watch this space 🌍 #KitePharma #GileadSciences #CellTherapy #Innovation #Biotechnology #Pharamceuticals #LifeScience #ElixirAssociates #StaffingPartner

🚀 Excited to share how MathCo tackled the challenge of inconsistent biomarker testing rates across cancer types and regions! Our data-driven analysis identified high-impact areas for intervention, leading to optimized resource allocation and improved precision medicine initiatives. Together, we can enhance patient care and outcomes in oncology! #BiomarkerTesting #PrecisionMedicine #HealthcareInnovation

By gathering frequent high-resolution data anywhere, PONS can power decentralized trials embedded into normal care routines. Ultimately this means achieving precision therapy guided by an individual's unique markers. The future of not just ultrasound but medical imaging will be defined by intelligence extraction - going far beyond just static pictures toward deep phenotyping. With our rapidly growing dataset and continued algorithm innovations, PONS aims to spearhead the next generation of imaging biomarkers propelling preventative early detection while reshaping therapeutic development. #therapeutics #digitalhealth #PONS #pharmaceutical #clinicaltrials

Shoutout to Andelyn Biosciences for this article in Cell & Gene shedding light on the challenges that often hinder advanced therapy development. Of particular significance to my work - the challenge of not identifying and codifying analytics early. CDMOs have a unique opportunity to differentiate their services by adopting novel analytical technologies right out of the gate. By embracing innovative analytical approaches, CDMOs can offer their clients the invaluable advantage of robust in-house analytical capabilities. A group with a comprehensive testing strategy is a must in order to shorten timelines and save valuable resources. In this industry, precision and efficiency are paramount. CDMOs equipped with advanced analytical tools can facilitate smoother, more streamlined development pathways for advanced therapies. Do you work for a CDMO? Do you wait for the sponsor to request a novel technology? Or do you seek to innovate in advance in order to attract new business? #CDMO #biomanufacturing #challenges #innovation #analytics

Interesting and extensive view of the latest trends in Biotech R&D areas. Neil Torbett and Hanjo Kim are some of the great visionaries sharing his views on this article by Labiotech.eu

Advancing In Vitro Diagnostics and Accelerating Drug Discovery with the Latest Microarray Technologies 🎥 Webinar Recording Now Available! 🎥 🔗 Watch it here: https://lnkd.in/endCXxPZ 📅 Missed our recent webinar? No worries! The recording is now live and ready for viewing. Dive into insightful discussions, expert tips, and actionable takeaways on cutting-edge microarray technologies. 📌 Remember to share with your network! Let’s keep the conversation going. 🚀 #InVitroDiagnostics #DrugDiscovery #MicroarrayTechnologies #SCHOTTMINIFAB #Diagnostics #LifeScience

Thoughts on this? >> Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #productmarketing #biotech

A very insightful article on the major challenges which CAR-T therapies are facing especially in the US. Such challenges can totally be different depending on the countries mainly due to its complex logistics. "Six CAR-T therapies targeting either CD19 or BCMA have reached the U.S. market to treat various blood cancers. Impressive efficacy data, wide reimbursement acceptance, earlier-line approvals and steady production expansions have fueled blockbuster revenue predictions. But drug developers and Wall Street may have underestimated the bottlenecks from the healthcare infrastructure needed to deliver a cell therapy, Leerink Partners analyst Daina Graybosch, Ph.D., warns." https://lnkd.in/gSD7iiFN

2 companies with a unified mission to realize the full potential of iPSCs 🚀 Ncardia - Focused on iPSCs for drug discovery (disease modeling, screening, efficacy, safety/toxicology) Cellistic - Focused on iPSCs for cell therapy (process development, manufacturing) Originally called Pluriomics, Ncardia was formed in 2011 to offer iPSC-derived products (and also services now!) for research applications. Then, in 2022, Cellistic was launched as Ncardia's allogeneic cell therapy manufacturing brand. Curious to learn more? Check out the website for each company (links in the comments ⬇) #drugdiscovery #celltherapy #biotechdiaries Hi, I'm Jeff Bissen (pronounced BEE-sen) 👋 I'm a life science professional with 10 years of experience - first in research, now on the business side of the industry. I also post almost every day about my perspectives on biotech. Interested? Follow my profile and subscribe to my weekly newsletter, Biotech Diaries: https://lnkd.in/e8r_WBP8 ***Views expressed in my newsletter are entirely my own and not necessarily held by any past, present, or future employer***

Thoughts on this? >> Ori Biotech, Cytiva separately unveil tech to accelerate cell therapy production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #healthcare #productmarketing